Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001072613-24-000885
Filing Date
2024-11-14
Accepted
2024-11-14 17:13:31
Documents
1
Group Members
ARCH VENTURE PARTNERS XII, L.P.ARCH VENTURE PARTNERS XII, LLCKEITH CRANDELLKRISTINA BUROWROBERT NELSENSTEVEN GILLIS

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND XII, L.P. - RAPPORT THERAPEUTICS, INC. -- SCH 13G arch-sch13g_18906.htm SC 13G 230181
  Complete submission text file 0001072613-24-000885.txt   231976
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund XII, L.P. (Filed by) CIK: 0001906837 (see all company filings)

EIN.: 873448430 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 1325 BOYLSTON STREET SUITE 401 BOSTON MA 02215
Business Address 1325 BOYLSTON STREET SUITE 401 BOSTON MA 02215 857-321-8020
Rapport Therapeutics, Inc. (Subject) CIK: 0002012593 (see all company filings)

EIN.: 880724208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-94532 | Film No.: 241464248
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)